Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.

Autor: Alexeev SM; N.N. Petrov NII of Oncology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation., Khorinko AV; SBHI of PK Perm Krai, Perm Krai Cancer Dispensary, Perm, Russian Federation., Mukhametshina GZ; SAHI Republican Clinical Cancer Dispensary of the Ministry of Healthcare of the Republic of Tatarstan, Kazan, Russian Federation., Shelepen KG; Brest Regional Clinical Cancer Dispensary, Volgograd, Russian Federation., Burdaeva ON; SBHI of Arkhangelsk Region Arkhangelsk Regional Clinical Cancer Dispensary, Arkhangelsk, Russian Federation., Kulik SA; KLPU City Cancer Dispensary of the City of Donetsk, Donetsk, DNR, Ukraine., Satheesh CT; Sri Venkateshwara Hospital, Bangalore, India., Srivastava K; King Georges Medical University, Lucknow, India., Vikranth M; City Cancer Center, Vijayawada, India., Kryukov F; JSC BIOCAD, Saint Petersburg, Russian Federation. kryukov@biocad.ru., Paltusova AN; JSC BIOCAD, Saint Petersburg, Russian Federation., Shustova MS; JSC BIOCAD, Saint Petersburg, Russian Federation., Ivanov RA; JSC BIOCAD, Saint Petersburg, Russian Federation.

Publikováno v: BMC cancer [BMC Cancer] 2020 Aug 20; Vol. 20 (1), pp. 783. Date of Electronic Publication: 2020 Aug 20.

Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.

Autor: Liu, Tong¹ (AUTHOR), Liu, Duo¹ (AUTHOR), Jin, Yao¹ (AUTHOR), Dong, Mei¹ (AUTHOR)

Publikováno v: Immunopharmacology & Immunotoxicology. Dec2022, Vol. 44 Issue 6, p809-815. 7p.

Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials.

Autor: Oliva A; Eu2P Programme, University of Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux, France. ANNAMARIA.MASCOLO@unicampania.it.; Department of Experimental Medicine, Section of Pharmacology 'L. Donatelli', University of Campania 'Luigi Vanvitelli', Via Costantinopoli 16, 80138, Naples, Italy. ANNAMARIA.MASCOLO@unicampania.it., Scavone C; Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Via Costantinopoli 16, 80138, Naples, Italy.; Department of Experimental Medicine, Section of Pharmacology 'L. Donatelli', University of Campania 'Luigi Vanvitelli', Via Costantinopoli 16, 80138, Naples, Italy., Riccardi C; Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Via Costantinopoli 16, 80138, Naples, Italy.; Department of Experimental Medicine, Section of Pharmacology 'L. Donatelli', University of Campania 'Luigi Vanvitelli', Via Costantinopoli 16, 80138, Naples, Italy., Bernardi FF; Directorate-General for Health Protection, Campania Region, 80143, Naples, Italy., Salvo F; INSERM, BPH, U1219 Team Ahead, University of Bordeaux, 33000, Bordeaux, France.; Department of Medical Pharmacology, CHU of Bordeaux, 33000, Bordeaux, France., Mascolo A; Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Via Costantinopoli 16, 80138, Naples, Italy.; Department of Experimental Medicine, Section of Pharmacology 'L. Donatelli', University of Campania 'Luigi Vanvitelli', Via Costantinopoli 16, 80138, Naples, Italy.; Department of Life Science, Health, and Health Professions, Link Campus University, Via del Casale di San Pio V, 44, 00165, Rome, Italy.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Sep 18. Date of Electronic Publication: 2024 Sep 18.

Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.

Autor: Díaz, Luis Pérez, Millán, Susana, Chaban, Nuran, Campo, Ana del, Spitzer, Eduardo

Publikováno v: Future Oncology; Jul2021, Vol. 17 Issue 19, p2529-2544, 16p

Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.

Autor: Chai Q; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 58, Pu Yu Dong Road, Shanghai, 200011, China., Wen H; Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China., Lang Y; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 58, Pu Yu Dong Road, Shanghai, 200011, China., Zhang L; Department of Nursing, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Shanghai, 200127, China., Song Y; Department of Nursing, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 160, Pujian Road, Shanghai, 200127, China. renji_song@126.com., Liu X; Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, No. 58, Pu Yu Dong Road, Shanghai, 200011, China. liuxiaoyanrj@sjtu.edu.cn.

Publikováno v: Clinical drug investigation [Clin Drug Investig] 2022 Nov; Vol. 42 (11), pp. 937-947. Date of Electronic Publication: 2022 Sep 17.